CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

NCT ID: NCT04104646

Last Updated: 2023-08-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-18
• Study Completion Date: 2021-12-13

Brief Summary

A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome

Detailed Description

This was a randomised, multicentre, double-blind, double-dummy, parallel-group, controlled study of CHF6563 (non-ethanolic buprenorphine) sublingual solution.

For the enrolled subjects, withdrawal signs were assessed using a pre-defined Finnegan Neonatal Abstinence Scoring Tool (FNAST). FNAST assessments were made in neonates who showed signs of withdrawal despite appropriate non-pharmacological care and were recorded every 4 hours (±1 hour). Pharmacological treatment was to be started up to 7 days after birth in neonates who showed signs of neonatal opioid withdrawal syndrome (NOWS), defined as the sum of three consecutive FNAST scores ≥24 or a single score ≥12, and had failed to respond to non-pharmacological care. After FNAST assessment had started, it was continued for at least 24 hours, even if the baby was not randomised.

Sublingual administration of CHF6563 (non-ethanolic buprenorphine) solution (0.075 mg/mL) at a starting dose of 10 μg/kg every 8 hours (q8), using birth weight and oral administration of morphine-matched placebo (sterile water for injection USP), every 4 hours (q4). Thereafter, up-titrations of CHF6563 were possible to a maximum scheduled dose of 90 μg/kg/day. At the discretion of the physician, rescue doses of CHF6563 or morphine could have been given during the treatment to a neonate who had a single score of ≥12. Duration of treatment could last a maximum of 10 weeks. Adverse events (AEs) and serious adverse events (SAEs) were collected starting from the time of informed consent signature or from the neonate's birth (if the informed consent was signed before birth) through treatment and the follow-up period.

The study was terminated for non-safety reasons on 04 February 2022, due to low recruitment rate, after only 7 subjects out of a planned 57 subjects had been randomised. An Independent Safety Monitoring Board (ISMB) was in-place to review the safety profile of CHF6563/morphine treatment; the study was terminated before the ISMB reviewed any data.

Conditions

Neonatal Opioid Withdrawal Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

CHF6563

Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo

Group Type: EXPERIMENTAL

CHF6563

Intervention Type: DRUG

Sublingual CHF6563 administration at starting dose of 10 µg/kg q8

Morphine matched placebo

Intervention Type: DRUG

Oral morphine matched placebo administration

Morphine

Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.

Group Type: ACTIVE_COMPARATOR

Morphine

Intervention Type: DRUG

Oral morphine administration at starting dose of 0.07 mg/kg q4

CHF6563 matched placebo

Intervention Type: DRUG

Sublingual CHF6563 matched placebo administration

Interventions

CHF6563

Sublingual CHF6563 administration at starting dose of 10 µg/kg q8

Intervention Type: DRUG

Morphine

Oral morphine administration at starting dose of 0.07 mg/kg q4

Intervention Type: DRUG

CHF6563 matched placebo

Sublingual CHF6563 matched placebo administration

Intervention Type: DRUG

Morphine matched placebo

Oral morphine matched placebo administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent obtained by parents/legal representative(according to local regulation) prior to or after birth.

2. Birth weight ≥ 3rd centile for gestational age (GA), according to the Centers for Disease Control and Prevention (CDC) growth chart

3. Gestational age ≥ 36 weeks

4. Exposure to opioids during the last month of fetal life

5. Signs of neonatal opioid withdrawal syndrome requiring treatment, and the sum of 3 consecutive FNAST scores is ≥ 24 or a single score ≥ 12

Exclusion Criteria

1. Familial history of prolonged QTc syndrome

2. Major congenital malformations or evidence of congenital infection

3. Signs of fetal alcohol spectrum disorders

4. Maternal alcohol abuse, defined as average of 3 or more drinks per week in the last 30 days

5. Medical illness at the time of randomization, including but not exclusively:

1. Neonatal hypoglycemia requiring intravenous glucose therapy

2. Neonatal respiratory illness requiring non-invasive or invasive respiratory support

3. Neonatal encephalopathy (including hypoxic ischemic encephalopathy or seizures

4. Severe hyperbilirubinemia-bilirubin at or above the exchange transfusion threshold as defined by the American Academy of Pediatrics (AAP)

5. Severe elevation of serum aminotransferases (more than twice the upper limit of the age appropriate aminotransferases reference range of the investigational site).

6. Proven or suspected early onset neonatal infection which will require more than 48 hours treatment with antibiotics

6. Unable to tolerate an oral or sublingual medication

7. Need for medications forbidden in this study protocol

8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk

9. Participation in another clinical trial of any medicinal product, placebo, experimental medical device or biological substance conducted under the provisions of a protocol on the same therapeutic target. The participation in studies involving diagnostic devices or treatments for conditions other than NOWS and Neonatal abstinence syndrome (NAS) may be permitted following an agreement with the Sponsor. Non-interventional observational studies are allowed

• Maximum Eligible Age: 7 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chiesi Farmaceutici S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Walter Kraft

Role: PRINCIPAL_INVESTIGATOR

Thomas Jefferson University

Locations

Clinical site 015

Las Vegas, Nevada, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CLI-06563AA1-02

Identifier Type: -

Identifier Source: org_study_id